ChinaDaily Briefs

Daily Brief China: Huafa Property Services Group, PDD Holdings, Trip.com Group , Nongfu Spring , Remegen , Stella International, Baidu, Evergreen Marine Corp, Bilibili , Greentown China and more

In today’s briefing:

  • Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here
  • PDD Holdings (PDD US): Earnings Call Spooks Investors. Is There More than Meets the Eye?
  • Trip.com (9961 HK): Stock Surged After 2Q24 Result, Upside Narrowed to 18%
  • Nongfu Spring (9633 HK): 1H24 Impacted by Defamation, But Finally the Public with Nongfu
  • Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China
  • The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 26)
  • [Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL
  • Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)
  • [Bilibili (BILI US, BUY, TP US$20) TP Change]: User Demographics&AI Drive China’s Video Instagram
  • Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China


Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here

By David Blennerhassett

  • Ahead of Huafa Property Services Group (982 HK)‘s Scheme Meeting tomorrow, the 28th August, 42.57% of shares outstanding moved out of CCASS on the 8th July.
  • One argument for Huafa trading wide-ish to terms is due to “suspicious” CCASS moves between the Offer announcement and the vote. 
  • Some investors even cite the Golden Throat Holdings (6896 HK) debacle. This is not a Golden Throat situation. Not even close. It is decidedly less interesting and benign.

PDD Holdings (PDD US): Earnings Call Spooks Investors. Is There More than Meets the Eye?

By Devi Subhakesan

  • PDD Holdings (PDD US) stock price nosedived 28.5% yesterday wiping away more than USD55 billion in market cap following Management’s call with investors.
  • During the call, the management guided towards weakening profits in the next quarters and stated that high revenue growth was unsustainable in the long term.
  • Investors however seemed to be spooked not by negative guidance on profitability/growth but by comments on impact of non-business factors and need to adapt to changing times etc.

Trip.com (9961 HK): Stock Surged After 2Q24 Result, Upside Narrowed to 18%

By Ming Lu

  • In 2Q24, total revenue increased by 14% YoY and hotel booking revenue increased by 20%.
  • We believe the company has been riding on the recovery of the travel market and will see historical high quarter in 3Q24.
  • We also believe the stock still has an upside of 18% after one day’s surge.

Nongfu Spring (9633 HK): 1H24 Impacted by Defamation, But Finally the Public with Nongfu

By Ming Lu

  • 1H24, Nongfu’s revenue growth rate fell to 8% YoY, because Wahaha launched a propaganda against Nongfu.
  • We believe the revenue growth will rise in 2H24 and 2025, as it seems that the public do not like the way Wahaha use.
  • We set an upside of 26% and a price target at HK$38 for the end of 2025.

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

By Smartkarma Research

For our next Corporate Webinar, we are glad to welcome RemeGen’s Chief Financial Officer, Mr. Tong Shaojing.

In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&A session.

The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.

About RemeGen

RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.


The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 26)

By David Mudd


[Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL

By Ying Pan

  • BIDU reported C2Q24 top line, non-GAAP operating profit and GAAP net income inline, 5.6% and 7.6% vs. our estimate and inline, 10% and 8.4% vs. consensus. 
  • Weak economy is only part of the problem. Weak monetization exists across the entire product line. 
  • We cut the TP to US$80 and reiterate SELL rating.

Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)

By Daniel Hellberg

  • Backed by strong US demand, spot container rates remain very firm
  • On top of higher average freight rates, carriers now enjoying lower fuel prices
  • Dispersion of returns on carrier shares is eye-opening, only a few performed

[Bilibili (BILI US, BUY, TP US$20) TP Change]: User Demographics&AI Drive China’s Video Instagram

By Ying Pan

  • Bilibili (BILI) reported C2Q24 revenue, GAAP operating profit, and GAAP net income in-line, 7.9%, 9.9% vs. our estimates and in-line, 12%, 18% vs. consensus. 
  • BILI’s unique, urban user base and video format give it strong competitive advantage. Further, revenue from <Three Kingdom> game will be significant.
  • We raise our TP to US$20 and reiterate BUY .  

Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars